Market Overview

XenoPort May Be Beneficiary of Biogen Patent Filings

Share:
Related BIIB
Benzinga's Volume Movers
Biogen Collaboration With Applied Genetic Is 'Interesting,' But Morgan Stanley Will Wait For More Data
Are Biotechs In A Bubble? (Seeking Alpha)
Related XNPT
XenoPort Reports HORIZANT Included in New Expert Recommendations on Prevention, Treatment of RLS Augmentation
Who's The Next Big Pharma Acquisition?

Brian Abrahams, a Wells Fargo analyst, believes that Biogen (NASDAQ: BIIB) MS pill patents will be a positive boost for XenoPort (NASDAQ: XNPT).

Further patent applications could provide patent protection until 2032 for Biogen's BG-12, which should benefit XenoPort's '829 drug, an earlier stage derivative of BG-12, with added protection from generic competition.

BIIB is currently up 1.5 percent in pre-market trading, while XNPT is currently unchanged.

Latest Ratings for BIIB

DateFirmActionFromTo
Jun 2015Leerink SwannMaintainsOutperform
Jun 2015Leerink SwannReiteratesOutperform
Apr 2015CitigroupMaintainsBuy

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: Analyst Color News FDA Analyst Ratings

 

Related Articles (BIIB + XNPT)

Around the Web, We're Loving...

Get Benzinga's Newsletters